F-box Protein Fbl3b: Versatile Drug Target and Potential Therapeutic Approach

Target Name: FBXL21P

NCBI ID: G26223

FBXL21P

F-box Protein Fbl3b: Versatile Drug Target and Potential Therapeutic Approach

The F-box protein Fbl3b, also known as FBXL21P, is a protein that plays a crucial role in various cellular processes. It is a key component of the F-box domain, which is a common structural feature found in proteins that contain a compact of 伪-helices and 尾-sheets. Fbl3b is a 21kDa polypeptide protein that belongs to the F-box protein family. Its unique structure makes it play an important role in a variety of biological processes.

Fbl3b plays a variety of biological functions in cells, including participating in cell signaling, DNA damage repair, cell cycle regulation, etc. During cell signaling, Fbl3b acts as a receptor and binds to a variety of signaling molecules, thereby mediating signal transduction pathways. During DNA damage repair, Fbl3b is involved in chromosome repair and cell mitosis progression. In addition, Fbl3b is also related to cell cycle regulation, playing a role in mitotic spindle formation and cell cycle progression.

In addition, Fbl3b is also closely related to the occurrence and development of various diseases. Studies have shown that Fbl3b mutations are closely related to the risk of various cancers, such as lung cancer, liver cancer, breast cancer, etc. In addition, the expression level of Fbl3b is closely related to the occurrence and development of various diseases, such as diabetes, obesity, neurodegenerative diseases, etc.

Fbl3b has attracted widespread attention as a new drug target. Many studies have explored the possibility of Fbl3b as a drug target and the direction of drug development. At present, some drugs targeting Fbl3b have entered the clinical research stage, such as bevacizumab, rituximab, etc. These drugs bind to the specific antigen of Fbl3b and inhibit the binding of Fbl3b to the target protein, thereby achieving the therapeutic effect of the disease.

However, there are also some challenges and limitations in drug research targeting Fbl3b. First, the expression level of Fbl3b is affected by many factors, such as age, gender, tumor type, etc., which makes it difficult to accurately predict the expression level of Fbl3b. Secondly, the expression levels of Fbl3b are different in various tumor types, which makes the research and application of Fbl3b as a drug target also have certain differences.

Nonetheless, Fbl3b, as a new drug target, has broad application prospects. With the development of technology and in-depth research, it is expected to provide new methods and ideas for the treatment of various tumors and cardiovascular diseases in the future.

Protein Name: F-box And Leucine Rich Repeat Protein 21, Pseudogene

Functions: Substrate-recognition component of the SCF(FBXL21) E3 ubiquitin ligase complex involved in circadian rhythm function. Plays a key role in the maintenance of both the speed and the robustness of the circadian clock oscillation. The SCF(FBXL21) complex mainly acts in the cytosol and mediates ubiquitination of CRY proteins (CRY1 and CRY2), leading to CRY proteins stabilization. The SCF(FBXL21) complex counteracts the activity of the SCF(FBXL3) complex and protects CRY proteins from degradation. Involved in the hypothalamic suprachiasmatic nucleus (SCN) clock regulating temporal organization of the daily activities (By similarity)

The "FBXL21P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL21P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets